A single point mutation leads to the amino acid change W to stop at amino acid number 901 by the numbering of isoform 1 (ISO1; 5.1Kb), or 1002 by the numbering of isoform 2 (ISO2; 5.4Kb).
Amino acid replacement: W?term.
G12010569A
G?A
W901term | rols-PA; W1232term | rols-PB; W1002term | rols-PC; W901term | rols-PD; W1002term | rols-PE; W1001term | rols-PF; W1131term | rols-PG; W900term | rols-PH; W1130term | rols-PI
W1002term,W901term
G to A nucleotide change at the second or third position of the Trp codon leads to a nonsense mutation (exact site of mutation unspecified). Site of nucleotide substitution in mutant inferred by FlyBase base on reported amino acid change.
Live imaging of rolsT627 mutants, which are capable of some myoblast fusion, indicates that fusion always follows actin focus formation and dissolution, as in wild-type.
Homozygous border cell clones show defects in migration.
In rolsT627 mutant embryos, mature, multinucleated muscle fibers are absent. Instead, a large number of unfused myoblasts are present by late stage 13. These unfused founder cells maintain the ability to differentiate and form elongated mononucleated myocytes. Fusion-competent myoblasts extend filopodia toward elongated mononucleated founder cells, suggesting that adhesion between fusion-competent myoblasts and founder cells is not affected. All skeletal muscles appear to be affected, but visceral muscles exhibit only minor defects in the first midgut constriction, and the dorsal vessel appears to be normal. rolsT321/Df(3L)vin4 embryos also have myoblast fusion defects.